Table 3.

(a) Reduced functional connectivity in patients after versus before BTX treatment (Post‐BTX vs. Pre‐BTX). (b) Increased functional connectivity in patients after versus before BTX treatment (Post‐BTX vs. Pre‐BTX)

Seed ROIs (AAL‐atlas)	Targets	Functional areas	Peak MNI coordinate (x y z)	Cluster size (voxel)	p
(a)
Pallidum L	Cerebellum 4 5, 6 L		−20 −56 −26	209	.0018
Pallidum R	Caudate L  >  R, Pallidum L and Putamen L		−02 +12 +02	233	.0004
Thalamus R	Cingulate gyrus (mid part) and supplemental motor area R	Ventral anterior and dorsal posterior cingulate cortex; premotor and supplementary motor cortex (BA 6, 24, 31)	+10 −10 +40	141	.0235
Cingulate gyrus, posterior part L	Cerebellum 4 5, 3 and brainstem L		−06 −34 −12	139	.0298
Cerebellum 3L	Superior and middle frontal gyrus R	Frontal eye field (BA 8)	+22 + 46 + 54	169	.0077
Cerebellum 10 L	Middle and superior frontal gyrus L	Frontal eye field, dorsolateral prefrontal cortex, premotor and supplementary motor cortex (BA 6, 8, 9)	−42 +14 +38	840	.0000
	Superior and inferior parietal lobule, angular and supramarginal gyrus and middle occipital cortex L	Parietal association cortex, associative visual cortex (BA 7, 19, 39, 40)	−38 −66 +48	574	.0000
	Middle and inferior frontal gyrus L	Orbitofrontal area (BA 11, 47)	−40 +40 −12	267	.0003
	Middle and inferior temporal gyrus L	Middle temporal gyrus (BA 21)	−64 −34 −14	137	.0187
(b)
Cerebellum 7b R	Inferior temporal gyrus and middle occipital gyrus R, fusiform gyrus R	Associative visual cortex (BA 37)	+60 −68 −10	174	.0207

Peak MNI coordinates of regions with reduced FC to a seed ROI (AAL‐atlas; p < 0.05, cluster p‐FWE‐corrected for multiple comparisons).

AAL, automated anatomic labeling; BA, Brodmann area; BTX, botulinum toxin; HC, healthy control; FWE, family‐wise error; L, left; MNI, Montreal Neurological Institute; pre‐BTX, before BTX treatment; post‐BTX, after BTX treatment; R, right; ROI, region of interest; vs., versus.